Tango Therapeutics, Inc. is a precision oncology company engaged in the discovery and development of drugs at tumor suppressor gene loss in patients with unmet medical need. The Company’s product candidates include TNG908 and ubiquitin-specific protease 1 (USP1). TNG908, is a synthetic lethal, small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), which is designed to work selectively in cancer cells with a methylthioadenosine phosphorylase (MTAP) deletion. MTAP-deletion occurs in all human tumors, including non-small cell lung cancer (NSCLC), mesothelioma, pancreatic cancer, cholangiocarcinoma and glioblastoma. The Company is focused on initiating a Phase I/II clinical trial. USP1 is a synthetic lethal target discovery screen for BRCA1-mutant breast cancer. The Company’s lead molecules also have activity in BRCA2-mutant patient derived xenografts, including both BRCA1 and BRCA2 mutant models that are intrinsically resistant to polymerase (PARP) inhibition.